{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:50Z","timestamp":1787027810215,"version":"build-2736575974"},"reference-count":68,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Diffuse large B-cell lymphoma (DLBCL) especially affects the older population. Old (\u226560 years) and very old age (\u226580 years) DLBCL patients often present high-risk molecular alterations, lower tolerability to conventional immunochemotherapy, and poor clinical outcomes. In this scenario, attenuated therapeutic strategies, such as the R-MiniCHOP and R-MiniCHOP of the elderly regimens, have emerged for this particularly fragile population. However, the responses, clinical outcomes, and toxicities of these regimens currently remain poorly understood, mainly because these individuals are not usually included in controlled clinical trials. Methods: This retrospective, observational, and single-center real-world study included 185 DLBCL, NOS patients older than 70 years treated at the largest oncology center in Latin America from 2009 to 2020. We aimed to assess the outcomes, determine survival predictors, and compare responses and toxicities between three different primary therapeutic strategies, including the conventional R-CHOP regimen and the attenuated R-MiniCHOP and R-MiniCHOP of the elderly protocols. Results: The median age at diagnosis was 75 years (70\u201397 years), and 58.9% were female. Comorbidities were prevalent, including 19.5% with immobility, 28.1% with malnutrition, and 24.8% with polypharmacy. Advanced clinical stage was observed in 72.4%, 48.6% had bulky disease \u22657 cm, 63.2% had B-symptoms, and 67.0% presented intermediate\u2013high\/high-risk IPI. With a median follow-up of 6.3 years, the estimated 5-year OS and PFS were 50.2% and 44.6%, respectively. The R-MiniCHOP of the elderly regimen had a lower ORR (p = 0.040); however, patients in this group had higher rates of unfavorable clinical and laboratory findings, including hypoalbuminemia (p = 0.001), IPI \u2265 3 (p = 0.013), and NCCN-IPI \u2265 3 (p = 0.002). Although associated with higher rates of severe neutropenia (p = 0.003), the R-CHOP regimen promoted increased OS (p = 0.003) and PFS (p = 0.005) in comparison to the attenuated protocols. Additionally, age \u2265 75 years, high levels of LDH, B-symptoms, advanced clinical stage (III\/IV), neutrophilia, and low lymphocyte\/monocyte ratio were identified as poor prognostic factors in this cohort. Conclusions: In this large and real-life Latin American cohort, we demonstrated that patients with DLBCL, NOS older than 70 years still do not have satisfactory clinical outcomes in 2024, with half of cases not reaching 5 years of life expectancy after diagnosis. Although the conventional R-CHOP offers response and survival advantages over attenuated regimens, its myelotoxicity is not negligible. Therefore, the outcomes reported and the prognostic factors here identified may assist clinicians in the appropriate selection of therapeutic strategies adapted to the risk for old and very old DLBCL patients.<\/jats:p>","DOI":"10.3390\/cancers16081459","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T03:29:04Z","timestamp":1712806144000},"page":"1459","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Predictors of Survival, Treatment Modalities, and Clinical Outcomes of Diffuse Large B-Cell Lymphoma in Patients Older Than 70 Years Still an Unmet Medical Need in 2024 Based on Real-World Evidence"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9228-3276","authenticated-orcid":false,"given":"Lu\u00eds Alberto","family":"de P\u00e1dua Covas Lage","sequence":"first","affiliation":[{"name":"Department of Hematology, Hemotherapy & Cell Therapy, Faculty of Medicine, University of S\u00e3o Paulo (FM-USP), S\u00e3o Paulo 05403000, Brazil"},{"name":"Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Faculty of Medicine, University of S\u00e3o Paulo (FM-USP), S\u00e3o Paulo 05403000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita Novello","family":"De Vita","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemotherapy & Cell Therapy, Faculty of Medicine, University of S\u00e3o Paulo (FM-USP), S\u00e3o Paulo 05403000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Bassolli","family":"de Oliveira Alves","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemotherapy & Cell Therapy, Faculty of Medicine, University of S\u00e3o Paulo (FM-USP), S\u00e3o Paulo 05403000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7006-9295","authenticated-orcid":false,"given":"Mayara D\u2019Auria","family":"Jacomassi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemotherapy & Cell Therapy, Faculty of Medicine, University of S\u00e3o Paulo (FM-USP), S\u00e3o Paulo 05403000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6850-8247","authenticated-orcid":false,"given":"Hebert Fabr\u00edcio","family":"Culler","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemotherapy & Cell Therapy, Faculty of Medicine, University of S\u00e3o Paulo (FM-USP), S\u00e3o Paulo 05403000, Brazil"},{"name":"Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Faculty of Medicine, University of S\u00e3o Paulo (FM-USP), S\u00e3o Paulo 05403000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-3928","authenticated-orcid":false,"given":"Cadiele Oliana","family":"Reichert","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Faculty of Medicine, University of S\u00e3o Paulo (FM-USP), S\u00e3o Paulo 05403000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5745-7843","authenticated-orcid":false,"given":"F\u00e1bio Alessandro","family":"de Freitas","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Faculty of Medicine, University of S\u00e3o Paulo (FM-USP), S\u00e3o Paulo 05403000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemotherapy & Cell Therapy, Faculty of Medicine, University of S\u00e3o Paulo (FM-USP), S\u00e3o Paulo 05403000, Brazil"},{"name":"Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Faculty of Medicine, University of S\u00e3o Paulo (FM-USP), S\u00e3o Paulo 05403000, Brazil"},{"name":"Funda\u00e7\u00e3o Pr\u00f3-Sangue, Blood Bank of S\u00e3o Paulo, S\u00e3o Paulo 05403000, Brazil"},{"name":"Department of Hematology & Hemotherapy, Churchill Hospital, Oxford University, Oxford OX3 7LE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila Aparecida Coelho","family":"Siqueira","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of S\u00e3o Paulo (FM-USP), S\u00e3o Paulo 05403000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"de Oliveira Costa","sequence":"additional","affiliation":[{"name":"Department of Hematology & Hemotherapy, Faculty of Medicine, Centro Universit\u00e1rio Lus\u00edada (Unilus), Santos 11045101, Brazil"},{"name":"Department of Hematology & Oncology, Hospital Alem\u00e3o Oswaldo Cruz (HAOC), S\u00e3o Paulo 05403000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0655-2821","authenticated-orcid":false,"given":"Juliana","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemotherapy & Cell Therapy, Faculty of Medicine, University of S\u00e3o Paulo (FM-USP), S\u00e3o Paulo 05403000, Brazil"},{"name":"Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Faculty of Medicine, University of S\u00e3o Paulo (FM-USP), S\u00e3o Paulo 05403000, Brazil"},{"name":"Department of Hematology & Oncology, Hospital Alem\u00e3o Oswaldo Cruz (HAOC), S\u00e3o Paulo 05403000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse Large B-Cell Lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"102443","DOI":"10.1016\/j.ctrv.2022.102443","article-title":"Treatment strategies for patients with diffuse large B-cell lymphoma","volume":"110","author":"Poletto","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","article-title":"Diffuse large B-cell lymphoma","volume":"87","author":"Martelli","year":"2013","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","article-title":"Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: Population-level projections for 2020-2025","volume":"63","author":"Kanas","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","article-title":"Aging, cellular senescence, and cancer","volume":"75","author":"Campisi","year":"2013","journal-title":"Annu. Rev. Physiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1126\/science.abn4009","article-title":"Epigenetic clocks, aging, and cancer","volume":"378","author":"Johnstone","year":"2022","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cmet.2022.11.001","article-title":"Meta-hallmarks of aging and cancer","volume":"35","author":"Pietrocola","year":"2023","journal-title":"Cell Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejim.2018.10.003","article-title":"Curing diffuse large B-cell lymphomas in elderly patients","volume":"58","author":"Moccia","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/17474086.2017.1305264","article-title":"Diffuse Large B-cell Lymphoma in the elderly: Standard treatment and new perspectives","volume":"10","author":"Chiappella","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11912-020-00976-x","article-title":"Diffuse Large B-Cell Lymphoma in the Elderly: Current Approaches","volume":"22","author":"Allen","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/cncr.22188","article-title":"Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma","volume":"107","author":"Grann","year":"2006","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/11531550-000000000-00000","article-title":"Non-Hodgkin\u2019s lymphoma in the elderly","volume":"27","author":"Caimi","year":"2010","journal-title":"Drugs Aging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: A prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.22.01848","article-title":"Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma","volume":"41","author":"Nastoupil","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"103294","DOI":"10.1016\/j.critrevonc.2021.103294","article-title":"Diffuse large B-cell lymphoma in very elderly patients: Towards best tailored treatment\u2014A systematic review","volume":"160","author":"Tavares","year":"2021","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"ref_19","first-page":"51","article-title":"Current Frontline Treatment of Diffuse Large B-Cell Lymphoma","volume":"36","author":"Spinner","year":"2022","journal-title":"Oncology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00277-012-1463-9","article-title":"The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma","volume":"91","author":"Lin","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993). A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N. Engl. J. Med., 329, 987\u2013994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/onco.13610","article-title":"Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients","volume":"26","author":"Di","year":"2021","journal-title":"Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s11899-019-00519-7","article-title":"Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly","volume":"14","author":"Khan","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: A multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/10428194.2011.600486","article-title":"Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older","volume":"53","author":"Meguro","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1082293","DOI":"10.3389\/fimmu.2022.1082293","article-title":"Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): A randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/annonc\/mdx128","article-title":"Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: Results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial","volume":"28","author":"Cunningham","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2011.08786.x","article-title":"Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high \u2018life threat\u2019 impact cardiopathy","volume":"154","author":"Corazzelli","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3109\/10428194.2011.621565","article-title":"Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly \u201cfit\u201d patients with diffuse large B-cell lymphoma: Results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi","volume":"53","author":"Merli","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/bjh.14232","article-title":"A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma","volume":"175","author":"Park","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","article-title":"De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: A United Kingdom National Cancer Research Institute trial","volume":"32","author":"Fields","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/S2352-3026(18)30054-1","article-title":"Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: A single-arm, open-label, phase 2 trial","volume":"5","author":"Shen","year":"2018","journal-title":"Lancet. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood.V114.22.408.408","article-title":"R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines","volume":"114","author":"Moccia","year":"2009","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/10428194.2013.788176","article-title":"Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi","volume":"55","author":"Merli","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/bjh.16049","article-title":"Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations","volume":"187","author":"Ong","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1634\/theoncologist.2011-0417","article-title":"Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma","volume":"17","author":"Spina","year":"2012","journal-title":"Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1634\/theoncologist.2011-0355","article-title":"Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA","volume":"17","author":"Olivieri","year":"2012","journal-title":"Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jgo.2013.04.003","article-title":"A retrospective study on 73 elderly patients (\u226575years) with aggressive B-cell non Hodgkin lymphoma: Clinical significance of treatment intensity and comprehensive geriatric assessment","volume":"4","author":"Marchesi","year":"2013","journal-title":"J. Geriatr. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","article-title":"Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: Results of the REAL07 open-label, multicentre, phase 2 trial","volume":"15","author":"Vitolo","year":"2014","journal-title":"Lancet. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3324\/haematol.2021.278288","article-title":"Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients\u2014A matched control multicenter cohort study","volume":"107","author":"Ram","year":"2022","journal-title":"Haematologica"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1182\/blood-2022-157768","article-title":"Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly\/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"140","author":"Olszewski","year":"2022","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1040-8428(00)00089-5","article-title":"The application of the principles of geriatrics to the management of the older person with cancer","volume":"35","author":"Balducci","year":"2000","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1002\/cncr.24490","article-title":"A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy","volume":"115","author":"Tucci","year":"2009","journal-title":"Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ejca.2005.01.010","article-title":"Independent prognostic effect of co-morbidity in lymphoma patients: Results of the population-based Eindhoven Cancer Registry","volume":"41","author":"Lemmens","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2141.2005.05508.x","article-title":"A population-based study of severity of comorbidity among patients with non-Hodgkin\u2019s lymphoma: Prognostic impact independent of International Prognostic Index","volume":"129","author":"Lemmens","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.16743","article-title":"Prognostic utility of a geriatric nutritional risk index in combination with a comorbidity index in elderly patients with diffuse large B cell lymphoma","volume":"192","author":"Lee","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1080\/10428194.2016.1185782","article-title":"Incidence of venous thromboembolism in patients with diffuse large B-cell lymphoma","volume":"57","author":"Borg","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3324\/haematol.2011.050617","article-title":"The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age","volume":"96","author":"Mareschal","year":"2011","journal-title":"Haematologica"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/blood-2011-10-388470","article-title":"Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma","volume":"119","author":"Klapper","year":"2012","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"10938","DOI":"10.21037\/apm-21-2551","article-title":"Relationship between the absolute lymphocyte count\/absolute monocyte count ratio, soluble interleukin 2 receptor level, serum programmed cell death 1 level, and the prognosis of patients with diffuse large B-cell lymphoma","volume":"10","author":"Li","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3000605221110075","DOI":"10.1177\/03000605221110075","article-title":"CD5+ diffuse large B-cell lymphoma has heterogeneous clinical features and poor prognosis: A single-center retrospective study in China","volume":"50","author":"Yin","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/ajh.21849","article-title":"Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil\/lymphocyte ratio","volume":"85","author":"Porrata","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/ajh.23566","article-title":"The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy","volume":"88","author":"Rambaldi","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Li, Z.M., Huang, J.J., Xia, Y., Sun, J., Huang, Y., Wang, Y., Zhu, Y.J., Li, Y.J., Zhao, W., and Wei, W.X. (2012). Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0041658"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1459\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:26:09Z","timestamp":1760106369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":68,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cancers16081459"],"URL":"https:\/\/doi.org\/10.3390\/cancers16081459","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,11]]}}}